<DOC>
	<DOCNO>NCT01974895</DOCNO>
	<brief_summary>The purpose study evaluate immunogenicity safety new influenza vaccine GSK2282512A ( FLU Q-QIV ) compare activity Sanofi Pasteur 's Fluzone® ( TIV ) child 6 35 month age .</brief_summary>
	<brief_title>Study Evaluate Immunogenicity Safety GlaxoSmithKline ( GSK ) Biologicals ' Quadrivalent Influenza Vaccine GSK2282512A When Administered Children From 6 35 Months Age</brief_title>
	<detailed_description>The subject randomise ( 1:1 ) two treatment group ( Q-QIV TIV-YB ) explore response vaccination .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects ' parent ( ) /Legally Acceptable Representative ( ) [ LAR ( ) ] , opinion investigator , comply , requirement protocol . A male female , include , 6 35 month age time first vaccination . Written inform consent obtain parent ( ) /LAR ( ) subject . Subjects stable health determine investigator 's clinical examination assessment subject 's medical history . Subjects eligible regardless history administration influenza vaccine previous season . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period . Routine register childhood vaccination permit . Child care . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . For corticosteroid , mean prednisone ≥ 0.5 mg/kg/day , equivalent . Inhaled topical steroid allow . Prior receipt seasonal pandemic influenza vaccine within six month precede first dose study vaccine , plan use study period . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period . History GuillainBarré syndrome within six week receipt prior influenza vaccine . Any known suspected allergy constituent influenza vaccine ; history anaphylactictype reaction consumption egg ; history severe adverse reaction previous influenza vaccine . Acute disease and/or fever time enrollment . Fever define temperature ≥ 38.0°C/100.4°F method . Subjects minor illness without fever may enrol discretion investigator . Any significant disorder coagulation treatment warfarin derivative heparin . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Any condition , opinion investigator , prevents subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>35 Months</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Children</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Fluzone®</keyword>
	<keyword>6 35 month age</keyword>
	<keyword>Seasonal influenza</keyword>
	<keyword>Safety</keyword>
</DOC>